Documents > FDA approval


Request for FDA Credentials Sample Memorandum

FDADocs 5/5/2008 | 0 (0) | 52 | 0 | 0 | English

Nomination and Approval of CBER Inspectors and Product Specialists Assigned to Conduct Inspections of Biological Products SOPP 8505 APPENDIX 2 MEMORANDUM Department of Health and Human Services Public Health Service Food and Drug Administration Center for Biologics Evaluation and Research ___________________________________________________________ ...  more>>

FDA Clinical Team Leader Memo Eric Bastings MD May 2005

FDADocs 5/9/2008 | 0 (0) | 51 | 0 | 0 | English

Eric P. Bastings, MD, HFD-120 21-645 Myzan (MT100) Memorandum ) Page 1 of MEMORANDUM DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Date: From: To: Subject: May 18, 2004 Eric Bastings, MD. Russell Katz, MD 21-645 Myzan (MT100) This submission is a new drug application (NDA) for the use of MYZAN (previou ...  more>>

AASLD FDA NIH PhRMA January Session I Non Presentations

FDADocs 5/12/2008 | 0 (0) | 25 | 0 | 0 | English

AASLD- FDA-NIH-PhRMA January 25-26, 2006 Session I: Non-Clinical Prediction (Moderator: Patrick Weir; Reporters: Frank Sistare and John Strong) P. Wier – Integrating Liver Toxicogenomics with Clinical Pathology and Histopathology in Preclinical Studies Q: Did you use a standard study design? A: The study was standard in terms of animals, husbandry  ...  more>>

AASLD FDA NIH PhRMA Hepatotoxicity Special Interest Group Meeting Agenda

FDADocs 5/12/2008 | 0 (0) | 32 | 0 | 0 | English

AASLD-FDA-NIH-PhRMA*- Hepatotoxicity Special Interest Group Meeting Brookside Gardens Conference Center,** Wheaton MD January 24 - 25, 2007 Issues and Conttroversiies iin DILI Issues and Con rovers es n DILI ((DIILII = drrug--iinduced lliiverr iinjjurry)) D L = d ug nduced ve n u y Wednesday, January 24, 2007 7:45 AM 8:15AM 8:20 AM CHECK-IN and CO ...  more>>

FDA Approval Of Second Generation Taxus Liberté Drug

ProfessionalDocument 10/11/2008 | 0 (0) | 63 | 0 | 0 | English

Boston Scientific Corporation today announced it has received approval from the U.S. Food and Drug Administration FDA to market its second-generation TAXUS Liberté Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the TAXUS Liberté stent early next month in the United States, following completion of the introduction of its ...  more>>

AASLD FDA NIH PhRMA January Session III Attribution Presentations

FDADocs 5/12/2008 | 0 (0) | 32 | 0 | 0 | English

AASLD- FDA-NIH-PhRMA January 25-26, 2006 Session III: Attribution of Causality (Moderator: Leonard Seeff; Reporters: Robert Fontana and David Lilienfeld) L. Seeff- Problems of Establishing Causality Establishing a diagnosis of DILI remains problematic in the absence of an objective and confirmatory laboratory test. Therefore, DILI is by definition  ...  more>>

FDA Proposed and Current Organizational Charts

FDADocs 5/8/2008 | 0 (0) | 44 | 0 | 0 | English

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION OFFICE OF THE COMMISSIONER OFFICE OF EQUAL OPPORTUNITY COMMISSIONER OF FOOD AND DRUGS Mark B. McClellan, M.D., Ph.D. DEPUTY COMMISSIONER Lester Crawford, D.V.M., Ph.D. PRINCIPAL ASSOCIATE COMMISSIONER Murray M. Lumpkin, M.D. OFFICE OF THE ADMINISTRATIVE LAW JUDGE PROPOSED DIRECT ...  more>>

FDA Organizational Chart

FDADocs 5/8/2008 | 0 (0) | 366 | 4 | 0 | English

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION OFFICE OF THE COMMISSIONER OFFICE OF EQUAL OPPORTUNITY COMMISSIONER OF FOOD AND DRUGS Mark B. McClellan, M.D., Ph.D. DEPUTY COMMISSIONER Lester Crawford, D.V.M., Ph.D. PRINCIPAL ASSOCIATE COMMISSIONER Murray M. Lumpkin, M.D. OFFICE OF THE ADMINISTRATIVE LAW JUDGE DIRECTOR Georgia ...  more>>

FDA Pharmacology Team Leader Memo Barry Rosloff PhD May 2005

FDADocs 5/9/2008 | 0 (0) | 24 | 0 | 0 | English

Barry N. Rosloff, Ph. D. 5/14/04 NDA 21-645 (MT 100) – SUPERVISORY MEMO I am in basic agreement with the analysis of and conclusions reached by Dr. Haberny (review of 5/13/04) regarding the preclinical data for MT 100. MT 100 is a combination of two relatively old drugs, naproxen (NAP) and metoclopramide (MET). In addition to the usual practice of  ...  more>>

Summary for Basis of Approval PDF MB Supplement Approval Hepatitis A Vaccine Inactivated Havrix

FDADocs 5/9/2008 | 0 (0) | 16 | 0 | 0 | English

SUMMARY FOR BASIS OF APPROVAL REFERENCE NUMBER: DRUG LICENSED NAME: MANUFACTURER 92-0465 HEPATITIS A VACCINE (INACTIVATED) SMlTHKLlNE BEECHAM BlOLOGlCALS HAVRIXTM DRUG TRADE NAME: HavrixTu (Hepatitis A Vaccine, Inactivated) is a whole-virion formaldehyde inactivated alum-adsorbed vaccine indicated for active . immunization against hepatitis A  ...  more>>

Summary for Basis of Approval

GovernmentDocs 5/4/2008 | 0 (0) | 34 | 0 | 0 | English

j i. Summary for Basis of Approval Reference Number: 90-0689 Dnra Licensed Name: Haemophi1us.b Conjugate Vaccine (Tetanus Toxoid Conjugate) Druq Trade Name: ActHlB Manufacturer: Pasteur Merieux Serums & Vaccins, S.A. ' Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), ActHIBTM, composed is of the purified capsular polysaccharide isola ...  more>>


   
  results / page   15/25/50 Page: 1 of 34 << prev 1234...34 next >>